The American Journal of Medicine
Volume 86, Issue 4 , Pages 376-378 , April 1989

High density lipoprotein cholesterol is reduced in patients with sarcoidosis

Received 13 July 1988 ,Accepted 10 January 1989.

References 

  1. Brown MS, Goldstein JL. Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem. 1983;52:223–261
  2. Shepherd J, Bicker S, Lorimer AR, Packarg CJ. Receptor-mediated low density lipoprotein catabolism in man. J Lipid Res. 1979;20:999–1006
  3. Slater HR, Packard CJ, Shepherd J. Receptor-independent catabolism of low density lipoprotein. In: Involvement of the reticuloendothelial system. 4th ed.. J Biol Chem. 257:1982;p. 307–310
  4. Rossner S, Lofmark G. Dyslipoproteinemia in patients with acute polyarthritis. In: A study on serum lipoproteins and triglyceride clearance. 4th ed.. Atherosclerosis. 28:1977;p. 41–52
  5. Svenson KLG, Lithel H, Hallgren R, Selinus I, Vessby B. Serum lipoprotein in active rheumatoid arthritis and othor chronic inflammatory arthritides. I. Relativity to inflammatory activity. Arch Intern Med. 1987;147:1912–1916
  6. Gilbert HS, Ginsberg H, Fagerstrom R, Brown WW. Characterization of hypocholesterolemia in myeloproliferative disease. In: Relation to disease manifestations and activity. 4th ed.. Am J Med. 71:1981;p. 595–602
  7. Gilbert HS, Ginsberg H. Hypocholesterolemia as a manifestation of disease activity in chronic myelogenous leukemia. Cancer. 1983;51:1428–1433
  8. Ginsberg H, Grabowski GA, Gibson JC, et al. Reduced plasma concentrations of total, low density lipoprotein- and high density lipoprotein cholesterol in patients with Gaucher type 1 disease. Clin Genet. 1984;26:109–116
  9. Ginsberg HN, Gilbert HS, Gibson JC, Le N-A, Brown MV. Increased low density lipoprotein catabolism myeloproliferative disorders. Ann Intern Med. 1982;71:595–602
  10. Le N-A, Gibson JC, Rubenstein A, Grabowskis GA, Ginsberg HN. Abnormalities in lipoprotein metabolism in Gaucher type 1 disease. Metabolism. 1988;37:240–245
  11. Ginsberg HN, Le N-A, Gilbert HS. Altered high density lipoprotein metabolism in patients with myeloproliferative disorders and hypocholesterolemia. Metabolism. 1986;35:878–882
  12. Ginsberg HN, Goldberg I, Wang-Iverson P, et al. Increased catabolism of native and cyclohexanedione modified low density lipoprotein in subjects with myeloproliferative disease. Arteriosclerosis. 1983;3:233–241
  13. Robinette CD, Fraimeni JF. Splenectomy and subsequent mortality in verterans of the 1939–1945 war. Lancet. 1977;II:127–129
  14. James DG, Turiaf J, Hosoda Y, et al. Description of sarcoidosis: report of the subcommittee on classification and definition. Ann NY Acad Sci. 1976;278:742
  15. Almenoff JA, Teirstein AS. Clinical significance of serum thermolysin-like metaloendopeptidase and its relationship to serum angiotensin converting enzyme in sarcoidosis. Am J Med. 1987;82:33–37
  16. Kindman LA, Gilbert HS, Almenoff JA, et al. Lipoprotein cholesterol abnormalities in sarcoidosis. (abstr) In: Proceedings of the 10th International Conference on Sarcoidosis and Other Granulomatous Disorders. 1984;
  17. Lipid Research Clinic Program . In: 4th ed.. Manual of laboratory operations, volume 1. Lipid and lipoprotein analysis. Bethesda: National Institutes of Health; 1974;DHEW publication no. (NIH) 75-678
  18. Heiss G, Tamir I, Davis CE, et al. Lipoprotein cholesterol distributions in selected North American populations: The Lipid Research Clinics Program Prevalence Study. Circulation. 1980;61:302–315
  19. Morrison A, Khoury P, Mellies M, Kelly K, Horvitz R, Glueck CJ. Lipid and lipoprotein distributions in black adults. In: The Cincinatti Lipid Research Clinics Princeton School Study. 4th ed.. JAMA. 245:1981;p. 939–942
  20. Teirstein AS, Siltzbach LE, Gabelman M, Lesser M. Socioeconomic factors influencing epidemiologic data in sarcoidosis among a mixed ethnic urban population. In:  Chretien J,  Marsac J editor. Sarcoidosis and other granulomatous disorders. Proceeding of the Ninth International Conference. Paris, August 31–September 4, 1981. Elmsford, New York: Pergamon Press; 1982;p. 234–236
  21. Tisi GM, Conrique A, Barrett-Conner E, Grundy SM. Increased high density lipoprotein cholesterol in obstructive pulmonary disease (predominant emphasematous type). Metabolism. 1981;30:340–346
  22. Svenson KLG, Lithell H, Hallgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease modifying drug treatment. Arch Intern Med. 1987;147:1917–1920
  23. Basu SK, Goldstein JL, Brown MS. Independent pathways for secretion of cholesterol and apolipoprotein E by macrophages. Science. 1983;219:871–873
  24. Nimer SD, Champlin RE, Golde DW. Serum cholesterol-lowering activity of granulocyte-macrophage colony stimulating factor. JAMA. 1988;260:3297–3300

☆ This work was supported, in part, by Grant RR-71 from the Division of Research Resources. General Clinical Research Center Branch. National Institutes of Health (H. Gilbert, H. Ginsberg, and R. Fagerstrom). The Jack Martin Fund and Grant CA-31656 from the National Institutes of Health (H. Gilbert), Medical Scientist Training Program Grant GM-07280 from the National Institute of Health (J. Almernoff), Grants HL-36000 and HL-21006 from the National Institutes of Health (H. Ginsberg), and The Henry and Catherine Gaisman Foundation (A. Teirstein). This work was reported in preliminary form at the 10th International Conference on Sarcoidosis and Related Disorders. Baltimore, Maryland, September 1984.

PII: 0002-9343(89)90332-X

doi: 10.1016/0002-9343(89)90332-X

The American Journal of Medicine
Volume 86, Issue 4 , Pages 376-378 , April 1989

Article Tools